DIRS.INFO The most relevant business & tech news

☆ ‘Ozempic babies’: What the science says on whether GLP-1s lead to surprise pregnancies, and their safety if they do
▼ + stars: | 2024-05-08 | by ( Mira Cheng | Meg Tirrell | ) edition.cnn.com time to read: +12 min

“I was depressed, severely depressed for that whole time.”Five months earlier, in October 2022, Bentley had started taking Mounjaro for weight loss. Ozempic uses the active ingredient semaglutide, and Wegovy is the version approved for weight loss. Mounjaro uses tirzepatide, which also targets a second hormone called GIP, and Zepbound is its brand name for weight loss. Safety in pregnancyEven as GLP-1 medicines may increase fertility, little is known about their safety during pregnancy. “It’s kind of like heart failure or sleep apnea,” he said, referring to conditions for which GLP-1 drugs have recently shown positive results.

Persons: CNN — Catera Bentley, Bentley, ”, “, ” Bentley, she’d, —, ‘, ’ Bentley, Jody Dushay, Dushay, Catera Bentley, Ivy, Daniel Drucker, ” Drucker, they’re, Drucker, Eli Lilly, ” Dushay, haven’t, That’s, Anuja Dokras, Dokras, Melanie Cree, Cree, PCOS, aren’t, Eli Lilly’s, Daniel Skovronsky, ” Skovronsky, Dr, Sanjay Gupta, it’s, Mounjaro Organizations: CNN, Beth Israel Deaconess Medical Center, Harvard Medical School, University of, Mount Sinai, Novo Nordisk, Zepbound, US Centers for Disease Control, University of Pennsylvania, PCOS, Children’s Hospital, National Institutes of Health, CNN Health Locations: Steele , Alabama, Mount, United States, Children’s Hospital Colorado, —, Colorado

☆ Ozempic Is Repairing a Hole in Our Diets Created by Processed Foods - The New York Times
▼ + stars: | 2024-05-07 | by ( Johann Hari | ) www.nytimes.com time to read: +1 min

So when I shrank from 203 pounds to 161 in a year, I was baffled by my feelings. I was taking Ozempic, and I was haunted by the sense that I was cheating and doing something immoral. But the fact that so many of us are turning to the new weight-loss drugs can be an opportunity to find a way out of that trap of shame and stigma — and to a more truthful story. I was born in 1979, and by the time I was 21, obesity rates in the United States had more than doubled. And how do these new weight-loss drugs work?

Persons: I’m, It’s Locations: United States

☆ Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
▼ + stars: | 2024-05-07 | by ( Eduardo Munoz | ) www.cnbc.com time to read: +3 min

A highly popular group of weight loss and diabetes drugs is still hard to find in the U.S. The dominant manufacturers of those treatments, Eli Lilly and Novo Nordisk , are making progress toward changing that. Patients using current autoinjectors for weight loss and diabetes drugs go through four different pens per month. Eli Lilly expects supply for Zepbound, Mounjaro and other incretin drugs to remain "quite tight" in the near- to mid-term as demand remains high, Ashkenazi said. On the day Eli Lilly reported earnings, shares of the company jumped more than 5% on the raised guidance and supply updates.

Persons: Eli Lilly, Anat Ashkenazi, There's, Ashkenazi, David Ricks, —, Lilly, Chris Schott Organizations: U.S, Novo Nordisk, Nexus Pharmaceuticals, JPMorgan Locations: North Carolina, Indiana, Ireland, Germany, Europe, U.S

☆ Dr. Gottlieb on Amgen's new weight loss drug: Expect to be on par with Wegovy & Mounjaro or better
▼ + stars: | 2024-05-06 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDr. Gottlieb on Amgen's new weight loss drug: Expect to be on par with Wegovy & Mounjaro or betterFormer FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss Amgen's new injectable weight loss drugs, how it takes a different approach from other weight loss drugs like Wegovy and Mounjaro, state of the obesity drug market, and more.

Persons: Gottlieb, Scott Gottlieb Organizations: FDA

☆ Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
▼ + stars: | 2024-05-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly , lower on Friday. Eli Lilly shares dropped nearly 3%, while Novo Nordisk's U.S.-traded shares fell more than 1%. Still, investors were pleased with Eli Lilly on Tuesday after the company assured them it can overcome ongoing supply constraints for its popular drugs. Eli Lilly hiked its full-year guidance in part due to optimism around increased production of Zepbound, its diabetes injection Mounjaro and similar drugs for the rest of the year. That signals Novo Nordisk is struggling to meet demand for the treatment.

Persons: Amgen, Eli Lilly, Bob Bradway, Bradway, Jay Bradner, autoinjector, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, William Blair, Matt Phipps, Michael Yee, Amgen's Bradway, Karsten Munk Knudsen Organizations: Novo Nordisk, Novo Nordisk's, Jefferies, MariTide, Nordisk Locations: Novo Nordisk's U.S, North Carolina, Indiana, Ireland, Germany, U.S

☆ Amgen soars 16% after it talks up a new weight loss drug that could be injected monthly instead of weekly
▼ + stars: | 2024-05-03 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug could be injected monthly instead of weekly. AdvertisementThe competition is fierce in the GLP-1 weight loss market, with Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjary and Zepbound dominating sales. AdvertisementWhile a monthly weight-loss injected drug may sound appealing to patients, it is likely still far from hitting the market, assuming it passes all of its clinical trials. And even more convenient than a monthly injection of GLP-1 would be a weight loss pill, though Amgen said it ditched development of its oral weight loss drug candidate to instead focus on the development of MariTide.

Persons: —, Amgen, Robert Bradway, Eli Lilly's Mounjary, Bradway, MariTide, James Bradner, Goldman Sachs, it's, hasn't Organizations: Service, Nordisk's Ozempic, Wall Street Locations: America

☆ Blockbuster weight loss drug Wegovy's sales just doubled — and could heat up even more with a price cut
▼ + stars: | 2024-05-03 | by ( Shubhangi Goel | ) www.businessinsider.com time to read: +3 min

Read previewDanish drugmaker Novo Nordisk will lower prices of its weight loss drug Wegovy as it plans to raise sales volumes and navigate tough competition. Prices for the blockbuster drug fell in the first quarter. Sales of Wegovy more than doubled in the first quarter year-on-year, to 9.4 billion Danish crowns, or $1.3 billion, according to the company's earnings. They did not specify how much Novo plans to cut Wegovy's prices. AdvertisementThe Danish pharmaceutical maker, which also produces viral weight loss drug Ozempic, reported better-than-expected sales of 65 billion Danish crowns, or $9.4 billion, in the first quarter.

Persons: —, Karsten Munk Knudsen, Knudsen, Lars Fruergaard Jorgensen, Ozempic, Eli Lilly, Wegovy, Bernie Sanders, Goldman Sachs, Oprah Winfrey, Elon Musk, Charles Barkley Organizations: Service, Nordisk, Business Locations: Danish, Novo

☆ Bausch Health investors are left in a holding pattern as 2 major overhangs remain unresolved
▼ + stars: | 2024-05-02 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

Bausch Health Companies on Tuesday morning reported first-quarter top- and bottom-line misses — putting embattled shares under pressure. BHC YTD mountain Bausch Health YTD Bottom line Along with quarterly results, Bausch Health reaffirmed forward guidance. While not necessarily expected to see a massive increase in adoption in the future like Lilly's GLP-1s, Xifaxan currently accounts for 41% of Bausch Health sales, excluding B+L. Breaking that down: $4.7 billion to $4.85 billion are attributable to Bausch Health (implying 2% to 5% organic growth), with $4.6 billion to $4.7 billion attributable to Bausch + Lomb. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Bausch, Eli Lilly, It's, Xifaxan, Jim Cramer's, Jim Cramer, Jim, Rafael Henrique Organizations: Health, Bausch Health, Norwich Pharmaceuticals, Amneal Pharmaceuticals, Food and Drug Administration, Management, CNBC Locations: generics, Norwich

☆ A millennial couldn't afford the Mounjaro weight-loss drug so he started secretly working 2 remote jobs. He's on track to make $166,000 this year and says he's lost 45 pounds.
▼ + stars: | 2024-05-01 | by ( Jacob Zinkula | ) www.businessinsider.com time to read: +6 min

A millennial in California is secretly working a second remote job so he can afford weight-loss drugs. AdvertisementLast August, George decided he wanted to try to work a second remote job — and not tell his employers he was job juggling. He was able to afford Mounjaro and said he's dropped 45 pounds — from 220 lbs to 175 lbs — since he started taking it in October. AdvertisementAfter a roughly monthlong search, he started his second job and was able to afford Mounjaro. Are you working multiple remote jobs at the same time and willing to discuss details about your pay and schedule?

Persons: Zepbound, —, George, Eli Lilly, he's, George hasn't, it's Organizations: Service, FDA, Nordisk's Ozempic, Business Locations: California, Mounjaro

☆ Eli Lilly assures investors it can overcome the high-quality problem of too much demand
▼ + stars: | 2024-04-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly 's raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. At their highs of the morning, shares of Eli Lilly traded above their all-time closing high of $792.28 set on March 4. In general, the more-bullish financial outlook helps make Eli Lilly's high price-to-earnings ratio coming into earnings more tolerable for investors. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: Eli Lilly, Eli Lilly's, Lilly, Jim Cramer, Lilly's, Jim, Anat Ashkenazi, Zepbound, It's, Ashkenazi, Dave Ricks, donanemab, Jim Cramer's, Eli Lilly’s, Brendan McDermid Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, U.S, Drug Administration, Nexus Pharmaceuticals, CNBC, FDA Locations: Eisai, Zepbound, Trulicity, Wisconsin, New York City, U.S

☆ Stocks making the biggest moves premarket: Eli Lilly, 3M, McDonald's and more
▼ + stars: | 2024-04-30 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Eli Lilly also hiked its full-year guidance for adjusted earnings and revenue, topping analysts' expectations. 3M – Shares advanced 7.7% after the maker of industrial products posted earnings of $2.39 per share on revenues of $7.72 billion. First-quarter revenue at the Netherlands-based automaker slid 12% due to lower sales plus foreign exchange effects, even as net pricing remained strong. HSBC — HSBC, Europe's largest bank by assets, added 4.2% after the firm beat first-quarter earnings expectations and announced the departure of its Group Chief Executive Officer, Noel Quinn. PayPal saw first-quarter revenue of $7.7 billion, topping analysts' $7.51 billion consensus estimate, according to LSEG.

Persons: Eli Lilly —, Eli Lilly, Meanwehile, Goldman Sachs, Coke, Tesla, Noel Quinn, Yun Li, Jesse Pound, Michelle Fox Theobald Organizations: Chrysler, HSBC — HSBC, GE Healthcare Technologies, GE, PayPal Locations: Chicago, Netherlands, Atlanta, China

☆ Eli Lilly soars 8% after Q1 earnings reveal surging popularity for its Zepbound weight-loss drug
▼ + stars: | 2024-04-30 | by ( Matthew Fox | ) www.businessinsider.com time to read: +4 min

The world's biggest healthcare company said it experienced surging demand for its GLP-1 Zepbound weight loss drug. Eli Lilly raised its 2024 revenue guidance, suggesting that the supply shortage of its weight loss drug may soon ease. The results showed soaring demand for its GLP-1 weight loss drug Zepbound, and the revenue guidance increase suggests that ongoing supply shortages of the drug may soon ease. "We have approximately 67% access in the commercial segment," Eli Lilly CFO Anat Ashkenazi said on the company's earnings call. Eli Lilly is looking to expand its indications of Zepbound so it can treat more health problems, including sleep apnea.

Persons: Eli Lilly, —, Zepbound, David Ricks, Eli Lilly's, Anat Ashkenazi, Ashkenazi, LLY, JPMorgan, JPMorgan isn't Organizations: Service, JPMorgan Locations: America

☆ Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro
▼ + stars: | 2024-04-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street's expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound. Eli Lilly also expects revenue for the year to come in between $42.4 billion and $43.6 billion, an increase of $2 billion at either end of the range. Shares of Eli Lilly jumped almost 8% in premarket trading Tuesday. With a market cap of about $700 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.

Persons: Eli Lilly, LSEG, They're Organizations: Analysts, LSEG Locations: San Diego , California, U.S

Eli Lilly — Shares added 5% after Eli Lilly, maker of the Mounjaro diabetes and weight loss drug, beat analysts' expectations for first-quarter adjusted earnings. PayPal — Shares gained 3.6% after the payment company posted $7.70 billion in first-quarter revenue, beating analysts' estimates for $7.51 billion, according to LSEG. The chipmaker posted adjusted earnings of $3.24 per share, higher than the consensus estimate of $3.16 per share, according to LSEG. Earnings of 24 cents per share on $1.37 billion in revenue exceeded consensus forecasts of 11 cents and $1.36 billion, according to FactSet. Adjusted earnings of 71 cents per share topped anticipated earnings of 65 cents per share.

Persons: Eli Lilly —, Eli Lilly, drugmaker, Jefferies, Tesla, Goldman Sachs, Tenet, Corning, FactSet, Sysco, Medifast, Paccar, Bob Bakish, Skydance, Needham, Macheel, Michelle Fox, Yun Li, Lisa Kailai Han, Pia Singh, Sarah Min Organizations: PayPal —, PayPal, Semiconductor, Tenet, FactSet, Technology, GE Healthcare Technologies, LSEG, Taco Bell, KFC, Paramount Global, CBS, Paramount Locations: Indianapolis, China, LSEG, FactSet, Houston

☆ Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentum
▼ + stars: | 2024-04-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Tirzepatide is the active ingredient in both Eli Lilly's diabetes treatment Mounjaro and its anti-obesity drug Zepbound. Based on that calculation, earnings will be lower by about 13 cents per share, he said, in research published last Tuesday. "Strong demand for Mounjaro & Zepbound can easily pull through in 2H24 and make up for any 1H24 shortfalls." For the week ended April 19, combined prescriptions of Mounjaro and Zepbound rose 63% year over year, according to IQVIA. Wells Fargo Mohit Bansal said he expects investors to look past any Trulicity shortfalls as the focus is firmily on Zepbound and Mounjaro for Lilly's future growth.

Persons: Eli Lilly, Eli, James Shin, Lilly, Shin, David Risinger, Zepbound, Wells, Bansal, Jo Walton, Walton, Lilly's, Tirzepatide, Deutsche Bank's Shin, — CNBC's Michael Bloom Organizations: Drug Administration, Deutsche Bank, IMS, UBS, Research, Deutsche, FDA Locations: 2H24, U.S

☆ 12 portfolio companies report earnings in the week ahead. What we want to hear from each
▼ + stars: | 2024-04-27 | by ( Zev Fima | ) www.cnbc.com time to read: +15 min

The action quickly and sharply reversed back to the upside Friday after blowout earnings reports from Alphabet and Microsoft . In the week ahead, earnings are likely to drive the action again, though we'll get a few important macroeconomic reports. Earnings: We've got the biggest week of the earnings season ahead of us, with 12 Club holdings set to report. Eli Lilly 's report Tuesday morning continues to be all about sales of type-2 diabetes treatment Mounjaro and weight-loss drug Zepbound. In DuPont 's report Wednesday morning, we're looking for a continued rebound in its semiconductor business following a sequential increase last quarter.

Persons: Ford, we'll, Dow Jones, We've, Buckle, Eaton, Eli Lilly, Lilly, We're, Estee Lauder, Fabrizio Freda, we've, Linde, Bausch, Royal Philips, Woodward, SIRI, Archer, Johnson, Stanley Black, Decker, BAX, Cardinal Health, Parker, Belden, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Microsoft, Meta, Google Search, Big Tech, Nvidia, Broadcom, Ford Motor, Honeywell, Danaher, Labor Department, Labor, PMI, Services PMI, GE Healthcare, Amazon Web Services, Starbucks, Deutsche Bank, DuPont, Bausch Health, U.S ., Appeals, Apple, iPhones, Vision, ON Semiconductor, Resource Partners, Franklin Resources, Paramount, Transocean Ltd, Semiconductors, Arch Capital, Logitech International, Lattice Semiconductor, F5 Networks, Sanmina Corporation, GE HealthCare, PayPal, 3M Company, McDonalds, Enterprise Products Partners, Cola Company, Melco Resorts, Entertainment, SiriusXM Holdings, Oatly, American Electric Power Company, Leidos Holdings, Marathon Petroleum, Daniels, Midland Co, Equitrans Midstream Corporation, HSBC Holdings, HSBC, Devices, Caesars Entertainment, Lumen Technologies, Mondelez, Pfizer, CVS Health, Barrick, Mastercard Inc, Cruise Line Holdings Ltd, Kraft Heinz Company, Marriott International, Ares, Generac Holdings, Johnson Controls, Cenovus Energy Inc, Qualcomm, Devon Energy, Paycom, Axcelis Technologies, Coeur D'Alene Mines, Sunnova Energy International, MGM Resorts International, MGM, Solar Inc, Oil, Allstate, Co, Tenable Holdings, Enovix Corporation, Gladstone Capital, Avis Budget Group, eBay, EBAY, LIN, Novo Nordisk, Natural Resources, PENN Entertainment, Apache, ConocoPhillips, InMode Ltd, Baxter International, Cardinal, Regeneron Pharmaceuticals, Apollo Global Management, LLC, Cinemark Inc, Dominion Energy, Coterra Energy, Coinbase, Bill.com Holdings, Booking Holdings, United States Steel, AXT Inc, Materials, Energy, Hershey Company, XPO Logistics, Cboe, American Pipeline, Amneal Pharmaceuticals, Brookfield Business Partners, Brookfield Renewable Corporation, Magna International, Jim Cramer's Charitable, CNBC, Traders, New York Stock Exchange, Bloomberg, Getty Locations: U.S, megaprojects, China, Eaton, Corning, Coeur D'Alene, Albemarle, ALB, Novo, New York

☆ Ozempic and Wegovy Have Health Benefits Beyond Weight Loss - The New York Times
▼ + stars: | 2024-04-24 | by ( David Wallace-Wells | ) www.nytimes.com time to read: +3 min

Last year was called the year of Ozempic, though it was also a year of Ozempic backlash and Ozempic shortages, which could persist for years. Even so, we appear very far from a peak for GLP-1 drugs, like Ozempic and Wegovy, which are powered by a molecule called semaglutide, and Mounjaro, which uses its cousin tirzepatide. It seems possible to imagine a future in which almost everyone is taking some variety of GLP-1 drug, and with a pretty good reason to do so. Patients on Ozempic and Wegovy can lose 15 to 20 percent or more of their weight in a little over a year, and if they stay on the drugs, the weight tends to stay off. Semaglutide has been shown to eliminate or reduce the need for insulin among those with recent-onset Type 1 diabetes.

Persons: tirzepatide, Wegovy, we’ve, Semaglutide Locations: Alzheimer’s

☆ Most people on weight loss drugs are spending less on restaurants and takeout, survey says
▼ + stars: | 2024-04-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Most people taking those medications, called GLP-1s, say they are spending less on eating out at restaurants and ordering takeout, according to a Morgan Stanley survey released on Tuesday. GLP-1s include Novo Nordisk 's blockbuster weight loss injection Wegovy and diabetes counterpart Ozempic, along with Eli Lilly 's popular weight loss treatment Zepbound and diabetes injection Mounjaro. "There is growing evidence that the drugs have a meaningful impact on consumer behavior and spending on groceries and restaurants," Morgan Stanley analysts said in the survey. Those people are "early in their weight loss journey," but are making substantial changes to their diets and spending, according to the firm. Roughly half of people reported cutting consumption of regular sodas, alcohol and salty snacks by 50% or more since starting on weight loss drugs.

Persons: —, Morgan Stanley, Eli Lilly, Hollie Adams, Reuters Morgan Stanley, Morgan Stanley survery Organizations: Washington Post, Novo Nordisk, Reuters, Consumers Locations: Manhattan, London, Britain

☆ These are the 10 most overvalued stocks in the S&P 500
▼ + stars: | 2024-04-18 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Shares of these companies would be considered overvalued, meaning they're trading at a current price that is not justified by their P/E ratio. Super Micro Computer trades at a 32.9 forward P/E, which is 173% above the five-year average P/E of 12.1. Microchip Technology is trading 73% above its five-year average P/E ratio of 15.8, while Broadcom is trading at a 58% premium. Eli Lilly is another overvalued name, as the stock is trading at a 71% premium to its five-year average. Other expensive stocks included in the list include copper producer Freeport McMoRan , pharmaceutical company Bristol-Myers Squibb and Tyson Foods .

Persons: Dow, Eli Lilly, Mounjaro, Eli Lilly's, Myers Squibb Organizations: Nasdaq, CNBC, Computer, Broadcom, Technology, Micro Computer, Bristol, Myers, Tyson Foods Locations: Freeport

☆ Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker says
▼ + stars: | 2024-04-17 | by ( Jen Christensen | ) edition.cnn.com time to read: +4 min

CNN —Zepbound, a popular weight loss drug, also seems to help people with obstructive sleep apnea, drugmaker Eli Lilly said Wednesday. Based on results from trials in people with sleep apnea, the company said it plans to submit the material to the US Food and Drug Administration to potentially expand the use of Zepbound for obstructive sleep apnea. Obstructive sleep apnea is a disorder that causes people to briefly stop breathing while they are sleeping, sometimes several times an hour. While people are more at risk for obstructive sleep apnea as they get older, it often develops when people gain weight and have overweight or obesity. Some doctors have been prescribing the weekly injection off label to people with obstructive sleep apnea, and Lilly has been testing the drug for obstructive sleep apnea since June 2022.

Persons: CNN —, Eli Lilly, Lilly, didn’t, Dr, Sanjay Gupta, CNN’s Meg Tirrell, Amanda Sealy Organizations: CNN, Food and Drug Administration, World Health, US Food and Drug Administration, CNN Health, American Diabetes Association

☆ Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says
▼ + stars: | 2024-04-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Most doses of Eli Lilly 's highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year as demand jumps, according to an update on the Food and Drug Administration's drug shortage database on Wednesday. All doses of Zepbound and Mounjaro besides the 2.5-milligram versions of both treatments are in a shortage. "We recognize this situation may cause a disruption in peoples' treatment regimens and areworking with purpose and urgency to help meet the surge in demand," an Eli Lilly spokesperson said in a statement to CNBC. The company expects its investments in manufacturing and supply capacity "to progressively increase production of our medicines throughout 2024 and beyond," they added.

Persons: Eli Lilly’s, Eli Lilly Organizations: Food, Novo Nordisk, CNBC Locations: New York City, U.S

☆ Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
▼ + stars: | 2024-04-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials. Zepbound was more effective than a placebo at reducing the severity of obstructive sleep apnea, or OSA, in patients with obesity after a year, according to preliminary data from both trials. Eli Lilly previously announced that the FDA granted Zepbound "fast track designation" for patients with moderate-to-severe OSA and obesity. Zepbound has slipped into shortages since receiving approval in the U.S. for weight management in November.

Persons: Eli Lilly’s, Eli Lilly, Zepbound, Dr, Jeff Emmick, Eli Lilly's Organizations: U.S . Food, Drug Administration, FDA, OSA Locations: New York City, U.S

☆ Another perk of weight-loss drugs? Eli Lilly's Zepbound may alleviate sleep apnea, too
▼ + stars: | 2024-04-17 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +4 min

GLP-1 drugs were originally developed to treat type 2 diabetes. Drugmakers are discovering the injections may also aid weight loss, heart issues, and sleep apnea. AdvertisementAnother new indication for injectable GLP-1 drugs: better sleep. On Wednesday, drugmaker Eli Lilly announced positive results from a large, phase-3 clinical trial, testing Zepbound (the drug name for tirzepatide) as a treatment for sleep apnea. Related storyAlready, GLP-1 drugs have been indicated for the treatment of:ObesityHeart diseaseAdvertisementIn clinical trials, GLP-1 drugs have also shown some promise for treating other conditions, including:Non-alcoholic fatty liver diseaseAddictionDepressionParkinson's and Alzheimer'sCancerThese breakthroughs may be tied to the gut-brain connectionScientists think that the main reason GLP-1 drugs work well is because of their effect on our body's gut-brain connection.

Persons: —, drugmaker Eli Lilly, Eli Lilly, KATERYNA, Daniel Drucker, GLP, Eric Topol Organizations: Service, Food and Drug Administration, American Diabetes Association, University of Toronto

☆ Promise of Eli Lilly's weight-loss drug for sleep apnea adds another reason to own the stock
▼ + stars: | 2024-04-17 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Eli Lilly said it plans to ask U.S. regulators to expand Zepbound's label to include obstructive sleep apnea, or OSA, later this year. Shares of Eli Lilly have ridden the GLP-1 craze to new heights over the past few years. The current standard of care for obstructive sleep apnea is positive airway pressure, or PAP, machines, which help keep patients' airways open while they sleep. Analysts projected obstructive sleep apnea revenue of $3 billion. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.

Persons: Eli Lilly, Zepbound, it's, Mounjaro, Lilly, Jim Cramer, Jim, Eli Lilly YTD, Morgan Stanley, Jim Cramer's, Eli Lilly’s, Brendan Mcdermid Organizations: Novo Nordisk, GLP, OSA, Mayo, U.S, CNBC, Cleveland Clinic, National Council, Aging, Deutsche Bank, American Diabetes Association, Novo Nordisk's Ozempic, Bank of America Locations: U.S, Novo, New York City

☆ EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
▼ + stars: | 2024-04-12 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

European Union drug regulators found no evidence that highly popular weight loss and diabetes drugs such as Wegovy and Ozempic are linked to an increased risk of suicidal thoughts and self-injury, the regulator said Friday. The review examined several drugs from Novo Nordisk , including Wegovy and Ozempic. Clinical trials from Novo Nordisk and Eli Lilly have not demonstrated a link between GLP-1s and suicidal thoughts. The probe also included other active ingredients in older weight loss and diabetes drugs, including dulaglutide, exenatide and lixisenatide. Results from another study conducted by the agency also did not support a link between GLP-1 drugs and the risk of suicidal thoughts.

Persons: Eli Lilly, couldn't, Liraglutide Organizations: Novo Nordisk, European Union, European Medicines Agency, U.S . Food, Drug Administration, EMA, Icelandic Medicines Agency Locations: London, Britain, Novo, U.S, GLP, Wegovy, Ozempic

Search resuls for: "Mounjaro"

25 mentions found